SENS Elliot Wave analysisSENS is a medical tech company focused on the design and development of glucose monitoring products designed to help people with diabetes.
Pricetarget wave 2 correction: $3.00
Pricetarget wave 3: $12-24.
The pricetarget of wave 3 will likely be driven by the US FDA approval coming march 2021. Hype will most likely drive the early stages of wave 3. Hopefully this hype will be backed up by fundamental growth of the company where it starts to make profits and scale in the market. If they don't get FDA approval this stock will most likely fall. High risk high reward play.
~slippe